FTH Faeth Therapeutics, Inc.
Nasdaq · SEC CIK 1829802 · EDGAR
- Bought, last 12 months
- $2.53M 7 purchases by 3 insiders
- Sold, last 12 months
- $2.28M 9 sales by 3 insiders
- Filings on record
- 151 since 2021-08-02, latest 2026-09-15 16:58
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 10% | $1.34M | $704.5K |
| STEPHENSON BRIAN C | CFO | $1.13M | — |
| Peyer James | 10%, See remarks below | — | $787.8K |
| Cambrian BioPharma Inc | 10% | — | $787.8K |
| Parikh Anand Kiran | Pres, CEO, Dir | $55.4K | — |
| Hahn Stephen M. | Dir | — | — |
Transactions 121
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-07-01 20:09 | 2026-06-29+ | FTH | STEPHENSON BRIAN C | CFO | P - Purchase | $23.92 | +13.6K | 46.7K | +41% | +$326.1K |
| MI | 2026-06-26 19:40 | 2026-06-24+ | FTH | STEPHENSON BRIAN C | CFO | P - Purchase | $25.65 | +15.6K | 33.1K | +90% | +$401.3K |
| MI | 2026-06-24 18:58 | 2026-06-22+ | FTH | STEPHENSON BRIAN C | CFO | P - Purchase | $23.31 | +17.4K | 17.4K | New | +$405.9K |
| D | 2026-06-24 18:55 | 2026-06-22 | FTH | Parikh Anand Kiran | Pres, CEO, Dir | P - Purchase | $19.76 | +2,806 | 764.2K | +0.4% | +$55.4K |
| DM | 2026-06-24 18:55 | 2026-06-22 | FTH | Parikh Anand Kiran | Pres, CEO, Dir | M - OptEx | $1.16 | +53.5K | 817.7K | +7% | +$62.0K |
| D | 2026-06-16 16:38 | 2026-06-15 | FTH | Parikh Anand Kiran | Pres, CEO, Dir | C - Cnv Deriv | — | +761.4K | 761.4K | New | — |
| D | 2026-06-16 16:21 | 2026-06-15 | FTH | Hahn Stephen M. | Dir | C - Cnv Deriv | — | +44.8K | 44.8K | New | — |
| M | 2026-06-01 17:21 | 2026-06-01 | FTH | Cambrian BioPharma Inc | 10% | S - Sale | $20.02 | -25.0K | 130.1K | -16% | -$500.5K |
| M | 2026-06-01 17:20 | 2026-06-01 | FTH | Peyer James | 10%, See remarks below | S - Sale | $20.02 | -25.0K | 130.1K | -16% | -$500.5K |
| MI | 2026-05-15 16:24 | 2026-04-02+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | P - Purchase | $33.54 | +4,215 | 134.0K | +3% | +$141.4K |
| MI | 2026-05-15 16:24 | 2026-04-02+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | S - Sale | $31.51 | -17.1K | 134.0K | -11% | -$538.1K |
| MI | 2026-05-15 16:22 | 2026-03-31+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | P - Purchase | $31.37 | +12.2K | 147.7K | +9% | +$382.1K |
| MI | 2026-05-15 16:22 | 2026-03-31+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | S - Sale | $28.07 | -2,741 | 147.7K | -2% | -$76.9K |
| MI | 2026-05-15 16:22 | 2026-03-26+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | P - Purchase | $26.75 | +30.6K | 145.7K | +27% | +$818.3K |
| MI | 2026-05-15 16:22 | 2026-03-26+ | FTH | MILLENNIUM MANAGEMENT LLC | 10% | S - Sale | $27.50 | -3,250 | 145.7K | -2% | -$89.4K |
| DM | 2025-12-10 | 2025-12-09 | FTH | Cambrian BioPharma Inc | 10% | S - Sale+OE | $8.25 | -6,612 | 155.6K | -4% | -$54.6K |
| D | 2025-12-10 | 2025-12-09 | FTH | Cambrian BioPharma Inc | 10% | M - OptEx | $6.40 | +395 | 156.0K | +0.3% | +$2,528 |
| DMI | 2025-12-10 | 2025-12-08+ | FTH | Peyer James | 10%, See remarks below | S - Sale+OE | $8.25 | -6,612 | 155.1K | -4% | -$54.6K |
| DI | 2025-12-10 | 2025-12-09 | FTH | Peyer James | 10%, See remarks below | M - OptEx | $6.40 | +395 | 156.0K | +0.3% | +$2,528 |
| MI | 2025-12-08 | 2025-12-04+ | FTH | Peyer James | 10%, See remarks below | S - Sale | $10.93 | -21.3K | 177.7K | -11% | -$232.7K |
| M | 2025-12-08 | 2025-12-04+ | FTH | Cambrian BioPharma Inc | 10% | S - Sale | $10.93 | -21.3K | 161.4K | -12% | -$232.7K |
| 2025-02-26 | 2025-02-19 | FTH | Celebi John | Pres AND CEO, Dir | F - Tax | $0.48 | -5,558 | 105.9K | -5% | -$2,668 | |
| 2025-02-26 | 2025-02-19 | FTH | van der Horst Edward | CSO | F - Tax | $0.48 | -2,276 | 59.8K | -4% | -$1,092 | |
| D | 2024-02-16 | 2024-02-15 | FTH | Celebi John | Pres AND CEO, Dir | F - Tax | $0.79 | -5,891 | 105.4K | -5% | -$4,654 |
| D | 2024-02-16 | 2024-02-15 | FTH | van der Horst Edward | CSO | F - Tax | $0.79 | -2,843 | 56.1K | -5% | -$2,246 |
| D | 2024-02-16 | 2024-02-15 | FTH | Colgan Erin | CFO | F - Tax | $0.79 | -3,627 | 67.5K | -5% | -$2,865 |
| 2023-09-13 | 2023-09-11 | FTH | Celebi John | Pres, CEO, Dir | P - Purchase | $0.85 | +500 | 111.3K | +0.5% | +$425 | |
| 2023-09-11 | 2023-02-15 | FTH | van der Horst Edward | CSO | F - Tax | $1.50 | -9,525 | 52.9K | -15% | -$14.3K | |
| 2023-09-11 | 2023-02-15 | FTH | Colgan Erin | CFO | F - Tax | $1.50 | -10.9K | 68.1K | -14% | -$16.4K | |
| 2023-09-11 | 2023-02-15 | FTH | Celebi John | Pres, CEO, Dir | F - Tax | $1.50 | -20.5K | 110.8K | -16% | -$30.7K | |
| 2023-09-11 | 2023-02-15 | FTH | Gallagher Patrick Stephen | Chief Business Off | F - Tax | $1.50 | -9,383 | 34.1K | -22% | -$14.1K | |
| 2023-08-02 | 2023-07-31 | FTH | Cambrian BioPharma Inc | 10%, See Remarks | D - Sale to Iss | $1.26 | -1.59M | 3.65M | -30% | -$2.00M | |
| I | 2023-08-02 | 2023-07-31 | FTH | Peyer James | Dir, 10% | D - Sale to Iss | $1.26 | -1.59M | 3.65M | -30% | -$2.00M |
| D | 2023-07-12 | 2023-07-10 | FTH | Humer Kristian | Dir | A - Grant | $0.00 | +4,466 | 8,932 | +100% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | Holmen Bob | Dir | A - Grant | $0.00 | +4,466 | 25.6K | +21% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | Vojta Deneen | Dir | A - Grant | $0.00 | +4,466 | 8,932 | +100% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | English Jessie | Dir | A - Grant | $0.00 | +4,466 | 8,932 | +100% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | RICKS THOMAS G | Dir | A - Grant | $0.00 | +4,466 | 8,932 | +100% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | Cambrian BioPharma Inc | 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | Broder Samuel | Dir | A - Grant | $0.00 | +4,466 | 8,932 | +100% | $0 |
| D | 2023-07-12 | 2023-07-10 | FTH | RINGO WILLIAM R | Dir | A - Grant | $0.00 | +4,466 | 23.4K | +24% | $0 |
| DI | 2023-07-12 | 2023-07-10 | FTH | Peyer James | Dir, 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| MI | 2023-06-02 | 2023-06-01 | FTH | Angermayer Christian | 10% | S - Sale | $1.58 | -3.44M | 0 | -100% | -$5.44M |
| DMA | 2023-03-29 | 2023-02-15 | FTH | Gallagher Patrick Stephen | Chief Business Off | A - Grant | $0.00 | +43.5K | 29.3K | New | $0 |
| DMA | 2023-03-29 | 2023-02-15 | FTH | Colgan Erin | CFO | A - Grant | $0.00 | +51.3K | 57.7K | +804% | $0 |
| DMA | 2023-03-29 | 2023-02-15 | FTH | Celebi John | Pres, CEO, Dir | A - Grant | $0.00 | +73.2K | 110.0K | +199% | $0 |
| DA | 2023-03-07 | 2022-06-10 | FTH | Cambrian BioPharma Inc | 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| MI | 2023-02-27 | 2023-02-23 | FTH | Apeiron Investment Group Ltd. | 10% | P - Purchase | $1.61 | +2,200 | 2.49M | +0.1% | +$3,542 |
| DM | 2023-02-17 | 2023-02-15 | FTH | Celebi John | Pres, CEO, Dir | A - Grant | $0.00 | +73.2K | 106.0K | +223% | $0 |
| DM | 2023-02-17 | 2023-02-15 | FTH | van der Horst Edward | CSO | A - Grant | $0.00 | +41.3K | 62.4K | +195% | $0 |
| DM | 2023-02-17 | 2023-02-15 | FTH | Gallagher Patrick Stephen | Chief Business Off | A - Grant | $0.00 | +43.5K | 43.5K | +2,175,650% | $0 |
| DM | 2023-02-17 | 2023-02-15 | FTH | Colgan Erin | CFO | A - Grant | $0.00 | +51.3K | 73.0K | +237% | $0 |
| DAI | 2022-08-01 | 2022-06-10 | FTH | Peyer James | Dir, 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | RICKS THOMAS G | Dir | A - Grant | $0.00 | +4,466 | 4,466 | New | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | Holmen Bob | Dir | A - Grant | $0.00 | +4,466 | 21.1K | +27% | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | Humer Kristian | Dir | A - Grant | $0.00 | +4,466 | 4,466 | New | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | English Jessie | Dir | A - Grant | $0.00 | +4,466 | 4,466 | New | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | Vojta Deneen | Dir | A - Grant | $0.00 | +4,466 | 4,466 | New | $0 |
| DI | 2022-06-14 | 2022-06-10 | FTH | Peyer James | Dir, 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | Cambrian BioPharma Inc | 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| D | 2022-06-14 | 2022-06-10 | FTH | Broder Samuel | Dir | A - Grant | $0.00 | +4,466 | 4,466 | New | $0 |
| A | 2022-06-10 | 2022-03-02 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $3.20 | +1,203 | 5.23M | +0.0% | +$3,850 |
| AI | 2022-06-10 | 2022-03-02 | FTH | Peyer James | Dir, 10% | P - Purchase | $3.20 | +1,203 | 5.23M | +0.0% | +$3,850 |
| A | 2022-04-21 | 2021-03-23 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $14.34 | +9,500 | 4.80M | +0.2% | +$136.2K |
| AI | 2022-04-21 | 2021-03-23 | FTH | Peyer James | Dir, 10% | P - Purchase | $14.34 | +9,500 | 4.80M | +0.2% | +$136.2K |
| A | 2022-04-21 | 2021-02-18 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $19.75 | +752 | 4.69M | +0.0% | +$14.9K |
| AI | 2022-04-21 | 2021-02-18 | FTH | Peyer James | Dir, 10% | P - Purchase | $19.75 | +752 | 4.69M | +0.0% | +$14.9K |
| DM | 2022-03-09 | 2022-03-08 | FTH | RINGO WILLIAM R | Dir | A - Grant | $0.00 | +18.9K | 18.9K | New | $0 |
| 2022-03-02 | 2022-03-02 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $3.20 | +1,203 | 5.23M | +0.0% | +$3,850 | |
| I | 2022-03-02 | 2022-03-02 | FTH | Peyer James | Dir, 10% | P - Purchase | $3.20 | +1,203 | 5.23M | +0.0% | +$3,850 |
| M | 2022-03-01 | 2022-02-28+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $3.60 | +2,500 | 5.23M | +0.0% | +$9,000 |
| MI | 2022-03-01 | 2022-02-28+ | FTH | Peyer James | Dir, 10% | P - Purchase | $3.60 | +2,500 | 5.23M | +0.0% | +$9,000 |
| 2022-02-28 | 2022-02-25 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $3.65 | +2,500 | 5.23M | +0.0% | +$9,125 | |
| I | 2022-02-28 | 2022-02-25 | FTH | Peyer James | Dir, 10% | P - Purchase | $3.65 | +2,500 | 5.23M | +0.0% | +$9,125 |
| M | 2022-02-24 | 2022-02-23+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $3.65 | +17.5K | 5.21M | +0.3% | +$64.0K |
| MI | 2022-02-24 | 2022-02-23+ | FTH | Peyer James | Dir, 10% | P - Purchase | $3.65 | +17.5K | 5.23M | +0.3% | +$64.0K |
| MI | 2022-02-22 | 2022-02-17+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.02 | +19.9K | 5.19M | +0.4% | +$80.2K |
| M | 2022-02-22 | 2022-02-17+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.02 | +19.9K | 5.21M | +0.4% | +$80.2K |
| D | 2022-02-17 | 2022-02-15 | FTH | Pierce Robert Hamilton | Chief R, D Off | A - Grant | $0.00 | +21.0K | 21.0K | New | $0 |
| D | 2022-02-17 | 2022-02-15 | FTH | Colgan Erin | CFO | A - Grant | $0.00 | +21.0K | 21.7K | +3,061% | $0 |
| D | 2022-02-17 | 2022-02-15 | FTH | Celebi John | Pres, CEO, Dir | A - Grant | $0.00 | +53.9K | 54.1K | +25,187% | $0 |
| 2022-02-16 | 2022-02-16 | FTH | Peyer James | Dir, 10% | P - Purchase | $4.25 | +2,551 | 5.19M | +0.0% | +$10.8K | |
| I | 2022-02-16 | 2022-02-14 | FTH | Peyer James | Dir, 10% | P - Purchase | $4.18 | +10.0K | 5.19M | +0.2% | +$41.8K |
| M | 2022-02-16 | 2022-02-14+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.19 | +12.6K | 5.19M | +0.2% | +$52.6K |
| M | 2022-02-14 | 2022-02-10+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.45 | +17.5K | 5.16M | +0.3% | +$77.9K |
| MI | 2022-02-14 | 2022-02-10+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.45 | +17.5K | 5.16M | +0.3% | +$77.9K |
| MI | 2022-02-08 | 2022-02-03+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.53 | +30.0K | 5.15M | +0.6% | +$135.8K |
| M | 2022-02-08 | 2022-02-03+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.53 | +30.0K | 5.16M | +0.6% | +$135.8K |
| M | 2022-01-31 | 2022-01-27+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.26 | +15.0K | 5.13M | +0.3% | +$63.8K |
| MI | 2022-01-31 | 2022-01-27+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.26 | +15.0K | 5.13M | +0.3% | +$63.8K |
| M | 2022-01-27 | 2022-01-25+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.72 | +50.0K | 5.11M | +1.0% | +$235.8K |
| MI | 2022-01-27 | 2022-01-25+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.72 | +50.0K | 5.08M | +1.0% | +$235.8K |
| MI | 2022-01-25 | 2022-01-21+ | FTH | Peyer James | Dir, 10% | P - Purchase | $4.82 | +47.4K | 5.06M | +0.9% | +$228.5K |
| M | 2022-01-25 | 2022-01-21+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $4.82 | +47.4K | 5.04M | +0.9% | +$228.5K |
| MI | 2022-01-21 | 2022-01-19+ | FTH | Peyer James | Dir, 10% | P - Purchase | $5.10 | +30.2K | 5.02M | +0.6% | +$154.3K |
| M | 2022-01-21 | 2022-01-19+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $5.10 | +30.2K | 5.02M | +0.6% | +$154.3K |
| 2022-01-20 | 2022-01-18 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $5.08 | +10.0K | 4.99M | +0.2% | +$50.8K | |
| I | 2022-01-20 | 2022-01-18 | FTH | Peyer James | Dir, 10% | P - Purchase | $5.08 | +10.0K | 4.99M | +0.2% | +$50.8K |
| M | 2022-01-18 | 2022-01-13+ | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $5.10 | +26.2K | 4.97M | +0.5% | +$133.4K |
| MI | 2022-01-18 | 2022-01-13+ | FTH | Peyer James | Dir, 10% | P - Purchase | $5.10 | +26.2K | 4.98M | +0.5% | +$133.4K |
Purchase Sale Sale after option exercise All abbreviations